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Cardiotrophin-1 (CT-1) isamemberof thegp130 family
of cytokines. We observed that ct-1/ mice develop
mature-onset obesity, insulin resistance, and hyper-
cholesterolemia despite reduced calorie intake.
Decreased energy expenditure preceded and accom-
panied the development of obesity. Acute treatment
with rCT-1decreasedbloodglucose inan insulin-inde-
pendent manner and increased insulin-stimulated
AKT phosphorylation in muscle. These changes were
associated with stimulation of fatty acid oxidation,
an effect thatwas absent inAMPKa2/mice.Chronic
rCT-1 treatment reduced food intake, enhanced en-
ergy expenditure, and induced white adipose tissue
remodeling characterized by upregulation of genes
implicated in the control of lipolysis, fatty acid oxida-
tion, and mitochondrial biogenesis and genes typi-
fying brown fat phenotype. Moreover, rCT-1 reduced
body weight and corrected insulin resistance in
ob/ob and in high-fat-fed obese mice. We conclude
that CT-1 is a master regulator of fat and glucose
metabolism with potential applications for treatment
of obesity and insulin resistance.
INTRODUCTION
It has recently been shown that the balance between calorie
procurement and disposal can be affected by gp130 receptor
ligands including interleukin-6 (IL-6) and ciliary neurotrophic
factor (CNTF). In particular, CNTF has been proposed as apoten-
tial therapy for obesity, glucose intolerance, and insulin resis-
tance (Febbraio, 2007). This cytokine induces weight loss by
hypothalamic control of energy balance (Janoschek et al.,
2006) and improves glucose tolerance by activating skeletal
muscle AMPK in chronic treatment (Watt et al., 2006). Notwith-
standing these effects, cntf null mice have not been reported242 Cell Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier Incto develop obesity (Masu et al., 1993). The role of IL-6 in obesity
and insulin resistance remains controversial. High circulating
levels of IL-6 have been observed in obesity and are associated
with the development of insulin resistance and type 2 diabetes,
both in humans and rodents (Kristiansen and Mandrup-Poulsen,
2005; Tilg andMoschen, 2006). However, the discovery that IL-6
is a myokine (Febbraio et al., 2004) produced (Hiscock et al.,
2004) and released (Steensberg et al., 2000) from skeletal
muscle during exercise led many to challenge this concept, as
insulin action is enhanced immediately after exercise (Wojtas-
zewski and Richter, 2006).
Cardiotrophin-1 (CT-1) is another member of the gp130 family
of cytokines. We and others have previously reported that this
cytokine is endowed with robust cytoprotective properties (Bus-
tos et al., 2003; In˜iguez et al., 2006; Marque`s et al., 2007; Penn-
ica et al., 1996). Although it has been suggested that CT-1 might
reduce insulin sensitivity in adipocytes (Zvonic et al., 2004),
contributing to the development of the metabolic syndrome in
humans (Natal et al., 2008), its role in lipid and glucose metabo-
lism has not yet been characterized.
In this study, we examined the metabolic features of ct-1 null
mice and the effects on body composition, glucose, and lipid
metabolism of acute and chronic administration of recombinant
CT-1 (rCT-1). Our data reveal that CT-1 is a regulator of energy
metabolism with potential applications in the treatment of
obesity and the metabolic syndrome.
RESULTS
CT-1Deficiency Is Associatedwith Adult-Onset Obesity,
Dyslipidemia, and Insulin Resistance
ct-1 null and wild-type (WT) mice showed similar body weight at
2 months of age, but in the former group obesity was apparent at
6 months and progressed with time (Figures 1A and 1B). The
analysis of body composition revealed that weight gain was
mainly due to increased adipose tissue (Figure 1C). Body fat
elevation was confirmed by weighing fat pads at different ages
(Figure 1D). As expected, serum leptin levels augmented signif-
icantly in ct-1/ mice in parallel with progression of adiposity
(Figure 1E)..
Figure 1. ct-1–/– Mice Develop Spontaneous Mature-Onset Obesity, and Young ct-1–/– Animals Exhibit Higher Susceptibility to Diet-Induced
Obesity
(A) Body weight of wild-type (WT) (,) and ct-1/ (-) male mice at various ages.
(B) Mice photographed at 12 months of age.
(C) Body composition of WT and ct-1/ mice at different ages analyzed by QMR technology (see Experimental Procedures).
(D) Weights of three different fat pads (epididymal, subcutaneous, and retroperitoneal) from WT and ct-1/ mice at different ages.
(E) Leptin levels in WT and ct-1/ mice at different ages (n = 6).
(F) Food intake in WT and ct-1/ mice at various ages (n = 11–13).
(G and H) Whole-body oxygen consumption rate (VO2) during 24 hr in WT and ct-1
/mice at 2 and 12 months of age (n = 4–8); #p < 0.05 represents differences
between the dark and the light cycle.
(I) Average values of energy expenditure (EE) for the 24 hr period in WT and ct-1/ mice at 2 and 12 months of age (n = 4–5).
(J) Physical activity for the 24 hr period in WT and ct-1/ mice at 2 and 12 months of age (n = 4–5).
(K) Average respiratory quotient (VCO2/VO2) (RQ) for the 24 hr period in WT and ct-1
/ mice at 2 and 12 months of age (n = 4–5).
(L) Fatty acid oxidation in soleus muscle in WT and ct-1/ mice at 2 and 12 months of age (n = 5).
(M and N) Body and fat pat weights of young WT and ct-1/mice (5 months old) fed with NCD (normal chow diet) and HFD (high-fat diet) for 12 weeks (n = 5–8).
Results are means ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 between WT and ct-1/ mice. (See also Figure S1 and Table S1.)
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CT-1 Regulates Glucose and Lipid MetabolismLongitudinal analysis of food intake from 2 to 12 months
showed that ct-1/ mice became obese despite reduced food
intake (Figure 1F), suggesting that energy expenditure (EE) could
be altered in these animals. Indeed, in 2-month-old ct-1 null
mice, oxygen consumption and EE were significantly reduced
in comparison with WT mice of the same age, and these differ-
ences increased in old animals (Figures 1G–1I). The differences
in oxygen consumption observed in 12-month-old mice (Fig-
ure 1H) were also prominent after normalizing by lean mass
(73.55 ± 0.87 versus 54.25 ± 0.58 ml/min/kg lean mass, p <
0.001). Changes in EE were not attributable to physical activity
(Figure 1J) nor to differences in BAT mass or expression in
BAT of genes involved in thermogenesis (data not shown), which
were similar in ct-1/ and WT mice at 2 months. Thus, our dataCelindicate that decreased EE precedes the development of obesity
in ct-1 null mice.
Notably, the respiratory quotient (RQ) was significantly
elevated in mature obese ct-1/ mice (Figure 1K), a finding
that was suggestive of reduced fat utilization. We found that
the fatty acid oxidative capacity of isolated skeletal muscle (as
estimated by the production of 14CO2 from [U-
14C]palmitate)
was comparable in WT and ct-1 null mice (Figure 1L). Thus, it
seems possible that the increase in RQmight be due to impaired
lipid mobilization. This concept is in agreement with the pres-
ence of lower circulating free fatty acids in old obese ct-1-defi-
cient mice (see Table S1 available online).
CT-1 deficiency strongly predisposes to obesity, as shown by
the fact that 2-month-old ct-1/ mice exposed for 12 weeks tol Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier Inc. 243
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CT-1 Regulates Glucose and Lipid Metabolisma high-fat diet (HFD) gained more weight and accumulated more
epididymal, retroperitoneal, and subcutaneous fatmass thanWT
animals (Figures 1M and 1N). Remarkably, ct-1/mice recapit-
ulate many of the features of the human metabolic syndrome,
including hypercholesterolemia, hyperglycemia, and hyperinsu-
linemia (Table S1), alterations that were observed from 6months
onward. Moreover, when young animals were exposed to HFD,
ct-1 null mice, but not WT animals, experienced a marked
increase in basal glycemia (212.4 ± 26.5 versus 110.80 ±
6.01 mg/dl, p < 0.05), insulinemia (2.08 ± 0.76 versus 0.58 ±
0.12 ng/ml, p < 0.05), and total cholesterol (314.8 ± 22.3 versus
158.0 ± 7.03mg/dl, p < 0.001), reflecting the decisive influence of
CT-1 on glucose and lipid metabolism. In ct-1/ mice on
a normal chow diet, pancreatic islet number and size were
increased at 9 and 12 months (Figure S1A), and the insulin toler-
ance test (ITT) was already altered at 6 months (Figure S1B). In
agreement with these findings, insulin-stimulated AKT phos-
phorylation was reduced in both skeletal muscle and WAT of
6-month-old ct-1/ animals (Figure S1C). These disturbances
were not present in nonobese 2-month-old ct-1 null mice
(Figures S1D and S1E), indicating that insulin resistance in
CT-1 deficiency is obesity dependent.
Reduced Expression of Lipolytic Genes and Impaired
Mitochondrial Biogenesis in WAT from Obese
ct-1-Deficient Mice
Mature ct-1/ mice showed adipocyte hypertrophy (Fig-
ure S1F). In WAT from these animals, there was a significant
reduction in the expression of adipose triglyceride lipase
(ATGL) and hormone-sensitive lipase (HSL), which are key exec-
utors of the hydrolysis of triglycerides (TG) and diglycerides
(Figure S1G). Isolated adipocytes from 2-month-old ct-1-defi-
cient mice showed no differences in basal and isoproterenol-
induced lipolysis when compared with WT adipocytes. In con-
trast, adipocytes from old obese ct-1 null mice responded poorly
to isoproterenol, although baseline lipolysis was increased (Fig-
ure S1H), as reported for hypertrophic adipocytes (Wueest et al.,
2009).
Genes involved in mitochondrial biogenesis, including peroxi-
some proliferator-activated receptor-g coactivator-1a (PGC-1a)
and endothelial nitric oxide synthase (eNOS), were downregu-
lated inWAT fromobese, but not young,ct-1/mice (FigureS1I).
In addition, mitochondrial DNA levels were reduced in WAT from
oldct-1/micecomparedwithWTanimals (FigureS1J). Further-
more, oxygen consumption was reduced in isolated adipocytes
from old obese ct-1 null mice, while this was not observed in
adipocytes fromyoung animals (Figure S1K). Altogether, our find-
ingssuggest that theobservedchanges in lipolysisandmitochon-
drial biogenesis are secondary to obesity and insulin resistance.
ct-1 Is a Nutritionally Regulated Gene: Effects of
Chronic CT-1 Treatment on Adipocyte Size, Fatty Acid
Oxidation, and WAT Remodeling
Since CT-1 deficiency leads to marked derangement in fuel
homeostasis, we asked whether CT-1 could be a nutritionally
regulated gene. In epididymal WAT we observed that ct-1
mRNA expression increased markedly when mice were sub-
jected to 48 hr fast and decreased promptly upon refeeding.
Similar changes were observed in skeletal muscle, liver, and244 Cell Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier Incheart in response to fasting and refeeding (Figure S2A), indi-
cating that CT-1 is regulated by nutritional status.
On the basis of these findings, we investigated the metabolic
effects induced by chronic treatment with rCT-1. We found that
intravenous (i.v.) administration of rCT-1 (0.2 mg/kg/day) for
6 days to 24-week-old male WT mice caused a significant
reduction in body weight (Figure 2A) and food intake (10.88 ±
0.51 versus 7.36 ± 0.96 kcal/day per mouse, p < 0.01). rCT-
1-treated mice lost significantly more weight than pair-fed
(PF) animals (Figure 2A), indicating that CT-1 enhanced energy
utilization besides reducing food intake. The doses of rCT-1
used in this study were comparable to those of CNTF able to
reduce food intake and body weight (Lambert et al., 2001;
Steinberg et al., 2006). After rCT-1 injection serum levels
were considerably above physiological values (2 mg/ml at
10 min after injection), the estimated rCT-1 half-life being
1.17 hr. Similarly to other anorexigenic cytokines (Lambert
et al., 2001), rCT-1 induced a hypophagic response when given
by either i.v. or intracerebroventricular (i.c.v.) injection. Accord-
ingly, we could observe activation of hypothalamic pathways
involved in hypophagia, including signal transduction acti-
vator of transcription 3 (STAT-3) and S6 ribosomal protein
(S6), 45 minutes after i.v. or i.c.v. administration of rCT-1
(Figure S2B).
To further elucidate the mechanisms underlying the slimming
properties of CT-1, we analyzed WAT histology and gene
expression in normal mice receiving saline, in mice treated with
rCT-1, and in PF animals. We found that the average adipocyte
size was smaller in rCT-1-treated animals even when compared
with the PF group (Figure 2B). Reduced adipocyte size corre-
lated with decreased expression of the lipogenic genes such
as fatty acid synthase (FAS), adipocyte determination and differ-
entiation-dependent factor 1 (ADD1), sterol CoA desaturase 1
(SCD1), and acetyl CoA carboxylase-a (ACCa) (Figure 2C). Fur-
thermore, mice given rCT-1 therapy showed increased expres-
sion of the lipolytic genes HSL and ATGL compared with PF
(Figure 2C).
In addition to regulating lipogenic and lipolytic genes, CT-1
seems to be able to modulate fat utilization in WAT. This was
suggested by the fact that two genes involved in fatty acid oxi-
dation, namely carnitine palmitoyl transferase I (CPT-1) and
acyl-CoA oxidase (ACO), were upregulated in WAT from rCT-
1-treated mice compared with PF group (Figure 2C). Consistent
with these data, fatty acid oxidation in WAT from rCT-1-treated
mice was increased as compared with PF group (Figure 2D).
Moreover, a direct stimulatory effect of rCT-1 on fatty acid oxida-
tion was also observed when adipose tissue fragments were
incubated with this cytokine (Figure S2C). Also, mitochondrial
biogenesis was enhanced in WAT from mice treated with
rCT-1 compared with PF animals. This was reflected by (1) upre-
gulation of genes implicated in the control of mitochondrial
function and regulation of BAT (PGC-1a, transcription factor A
mitochondrial [TFAM], NRF1, eNOS, uncoupling protein [UCP]
2, UCP1, PRDM16, and deiodinase iodothyronine type II
[Dio2]) (Figure 2E), (2) increased content of the mtDNA-encoded
COX1, (3) higher mitochondrial mass as estimated by Mito-
Tracker Green FM labeling, and (4) increased oxygen consump-
tion by isolated adipocytes of animals given rCT-1 (Figures
2F–2H). In vitro studies using 3T3-L1 adipocytes showed that.
Figure 2. Chronic Exposure to rCT-1 Decreases Body Weight and Induces a Marked Metabolic Remodeling in WAT
(A) Body weight changes after daily rCT-1 i.v. treatment (0.2 mg/kg/day) for 6 days in 24-week-old WT mice in comparison to saline-treated control mice fed ad
libitum and saline-treated mice pair-fed (PF) to the amount of food consumed by the rCT-1-treated group (n = 6).
(B) H&E-stained (1003) paraffin-embedded sections of epididymal WAT from saline, rCT-1-treated animals, and PF group. Distribution of adipocyte size.
(C) Relative expression of genes encoding key factors in lipogenesis, lipolysis, and fatty acid oxidation in epididymal WAT from saline, rCT-1-treated, and PF
mice. Data are expressed as fold change relative to saline-treated control mice fed ad libitum considered as 1 (dotted line) (n = 6).
(D) Fatty acid oxidation in epididymal fat from saline, rCT-1-treated animals, and PF mice (n = 5).
(E) Relative mRNA levels of genes involved in mitochondrial biogenesis and brown adipose tissue-specific genes in WAT of saline (considered as 1), rCT-1-
treated, and PF mice (n = 6).
(F) Representative western blot and densitometric analysis of COX1 in WAT from saline, rCT-1-treated, and PF mice.
(G) Epididymal adipocytes isolated from rCT-1-treated mice contain more mitochondria, as indicated by MitoTracker labeling. Data are presented as area under
curve (AUC) of RFU (relative fluorescent units) normalized by 106 cells (n = 8–11).
(H) Oxygen consumption in adipocytes from saline, rCT-1-treated, and PF group. Data are presented as area under curve (AUC) of RFU (relative fluorescent units)
normalized by 106 cells (n = 10). Results are means ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 PF versus rCT-1-treated group. (See also Figure S2.)
Cell Metabolism
CT-1 Regulates Glucose and Lipid MetabolismCT-1, but not CNTF, was able to upregulate Dio2 andUCP1, two
BAT characteristic genes (Figure S2D).
CT-1 Increases Fatty Acid Oxidation in Muscle
To test whether the body-weight-lowering activity of CT-1 is
accompanied by a stimulatory effect on fat utilization, we deter-
mined RQ changes in the fasting state after a single i.v. dose of
rCT-1 (10 mg/mouse). Mice receiving rCT-1 showed a significant
reduction of mean RQ compatible with activation of fatty acid
oxidation (Figure 3A) and exhibited, at 3 hr after rCT-1 injection,
marked upregulation of skeletal muscle genes involved in this
process, namely PGC-1b, ACO, acyl-CoA dehydrogenase
(ACD), and medium-chain acyl-CoA dehydrogenase (MCAD)
(Figure 3B). To confirm that CT-1 might enhance fat utilization,
we fed animals with a high-fat/sucrose meal while injecting i.v.
a single dose of rCT-1 (10 mg/mouse) or saline, and RQ wasCelmeasured over the following 8 hr. We found that RQ was lower
in rCT-1-treated mice than in controls (Figure 3C), indicating
stimulation of postprandial FFA oxidation. In addition, after
a high-fat/sucrose meal, saline-treated animals showed the ex-
pected postprandial rise in plasma FFA and TG, while in those
receiving rCT-1 serum, TG failed to increase, and serum FFA
experienced a rapid and pronounced decline after the meal (Fig-
ure 3D). To rule out decreased fat absorption as responsible for
these postprandial changes in serum lipids, we administered an
intravenous bolus of Lipofundin (a lipid emulsion), and the decay
of plasma FFAs after the injection was monitored in mice treated
30 min before with either rCT-1 (10 mg/mouse) or saline. We
observed that rCT-1 caused a marked acceleration in the
removal of FFAs from plasma (Figure 3E).
AMPK is considered to be a master regulator of fatty acid
oxidation (Viollet et al., 2009).We found that acute administrationl Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier Inc. 245
Figure 3. Effects of Acute Treatment with rCT-1 on Energy and Lipid Metabolism
(A) Average respiratory quotient (RQ) pre- and post-rCT-1 administration (10 mg/mouse, i.v.) to fasted WT mice. After a 14 hr acclimation period, VO2 and VCO2
were measured during 3–4 hr. After confirming the stability of RQ, rCT-1 or saline was administered and calorimetry was performed during 6 hr (n = 5).
(B) Peroxisome proliferator-activated receptor-g coactivator-1b (PGC-1b), acyl-CoA dehydrogenase (ACD), acyl-CoA oxidase (ACO), and medium-chain acyl-
CoA dehydrogenase (MCAD) mRNA levels in skeletal muscle 3 hr after rCT-1 administration (n = 5).
(C) RQ after a high-fat/sucrose meal given by gavage in saline and rCT-1-treated WT mice (n = 9–12).
(D) Effect of rCT-1 on serum FFA and TG levels in WT mice after a high-fat/sucrose meal (n = 5).
(E) rCT-1 treatment accelerates the removal of serum FFAs. Five minutes after Lipofundin injection, FFA levels raised from 0.73 ± 0.05 to 2.25 ± 0.31mM in saline-
treated animals and from 0.70 ± 0.08 to 2.62 ± 0.49 mM in rCT-1-treated animals. Clearance of FFA from serummeasured at later time points was normalized to
FFA levels at 5 min after Lipofundin injection (100%). Statistical analyses for (C)–(E) were performed by repeated-measures two-way ANOVA with Bonferroni
posttest (*p < 0.05).
(F) Phospho-AMPK (Thr172) and phospho-ACC (Ser79) signaling in skeletal muscle at 1 hr after a single dose of rCT-1 in fasted WT mice (n = 5).
(G) Palmitate oxidation in isolated skeletal muscle fromWT andAMPKa2/mice in the absence or presence of rCT-1 (20 ng/ml) (n = 5). Results aremeans ± SEM;
*p < 0.05, ***p < 0.001. (See also Figure S3.)
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CT-1 Regulates Glucose and Lipid Metabolismof rCT-1 stimulated the phosphorylation of AMPK and its down-
stream target ACC in skeletal muscle (Figure 3F). Moreover,
palmitate oxidation was significantly increased in isolated soleus
muscle incubated with rCT-1 as compared with contralat-
eral muscle incubated with saline (Figure 3G). Since in skeletal
muscle the actions of AMPK are thought to be mediated mainly
through the AMPKa2 isoform (Wojtaszewski et al., 2002), we
performed palmitate oxidation in the soleus muscle from
AMPKa2/mice in the presence or absence of rCT-1.We found
that rCT-1 treatment increased palmitate oxidation only in WT
but not in AMPKa2/mice, indicating that AMPK a2 is essential
for rCT-1 to stimulate fatty acid oxidation (Figure 3G).
Leptin has been shown to induce the expression of genes
involved in fatty acid oxidation through central activation (Mino-
koshi etal., 2002). Inorder to investigatewhether rCT-1couldexert
similar effects, we placed a cannula into the lateral ventricle of
C57BL/6mice and injected rCT-1 (1 mg) or saline i.c.v. At 6 hr after
infusion, we found no change in mRNA levels of PGC-1b, ACO,
ACD, or MCAD in skeletal muscle (Figure S3), signifying that
rCT-1 modulates fatty acid oxidation mainly by peripheral effects.246 Cell Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier IncCT-1 Regulates Glucose Homeostasis
The effect of CT-1 on glucose homeostasis was analyzed by
determining plasma glucose and insulin 1 hr after a single i.v.
dose of rCT-1 (10 mg/mouse) or saline to WT mice. We detected
a significant decrease of plasma glucose without changes in
insulin levels following rCT-1 administration (Figure 4A). The
insulin-sensitizing activity of CT-1was associated with activation
of AKT in skeletal muscle of rCT-1-treated mice (Figure 4B). The
effect of CT-1 in facilitating the action of insulin was also
confirmed by injecting rCT-1 (10 mg/mouse) 30 min before per-
forming an ITT in 6-month-old WT mice. rCT-1 was able to
decrease significantly the rise in glucose concentrations during
the rebound phase of the test (Figure 4C). The glycemia-lowering
properties of rCT-1 were confirmed in two additional models.
In animals given a high-fat/sucrose meal, the administration of
rCT-1 significantly decreased postprandial plasma glucose
levels (Figure 4D). Moreover, in mice with streptozotocin (STZ)-
induced insulin deficiency, the administration of rCT-1 caused
a significant fall in plasma glucose (Figure 4E), demonstrating
an insulin-independent effect of CT-1 on glucose homeostasis..
Figure 4. Glucose-Lowering Effects of rCT-1 in Different Models
(A) rCT-1 modifies insulin signaling in muscle and adipose tissue. Glucose and insulin levels at 1 hr after a single dose of rCT-1 (10 mg/mouse) in fasted WT mice
(n = 5).
(B) Ser473-phosphorylated AKT (P-AKT) in skeletal muscle in the same animals.
(C) ITT in WT mice (6 month s old) injected with rCT-1 (n = 5).
(D) Effect of rCT-1 on serum glucose levels after a high-fat/sucrose meal (n = 4).
(E) Changes in glucose levels in STZ-treated mice after the injection of rCT-1, insulin, or both (n = 5).
(F) FastedWTmice were injectedwith saline or rCT-1 for 30min, then insulin (0.5 U/mouse) was injected through the inferior vena cava. P-AKT signaling in skeletal
muscle and WAT was assessed by immunoblot analysis and quantified by densitometry (n = 5).
(G) P-AKT signaling in muscle and WAT from rCT-1 (0.2 mg/kg/day) or saline (PF)-treated animals for 6 days, fasted for 16 hr, and injected with insulin
(0.5 U/mouse) in the inferior vena cava (n = 5).
(H) rCT-1 effects on 2-deoxyglucose (2DG) uptake in L6E9myotubes in the absence or presence of insulin (n = 6); *p < 0.05, **p < 0.01, ***p < 0.001 versus control
cells, and #p < 0.05 versus insulin-treated cells.
(I and J) Representative western blots and densitometric analysis of P-AKT signaling in L6E9myotubes treated with rCT-1 and insulin for 15min or pretreated with
rCT-1 (20 ng/ml) for 10 and 24 hr and stimulated with insulin for 5 min.
(K) Effect of AKT inhibitor LY294002 (50 mM) on 2DG uptake in isolated soleus muscle incubated with 20 ng/ml of rCT-1 (30 min) in the absence or presence of
insulin (100 nM). Results are means ± SEM; *p < 0.05, **p < 0.01. (See also Figure S4.)
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CT-1 Regulates Glucose and Lipid MetabolismIn addition, we found that treatment with rCT-1 (10 mg/mouse)
30 min prior to insulin stimulation (0.5 U/mouse injected through
the inferior vena cava) resulted in increased insulin-induced AKT
phosphorylation in muscle but not in adipose tissue (Figure 4F).
Similarly, we observed stronger insulin-induced AKT phosphor-
ylation in skeletal muscle in animals subjected to chronic admin-
istration of rCT-1 (0.2 mg/kg/day) for 6 days compared with PF
mice given saline (Figure 4G). To better characterize the role of
CT-1 in regulating insulin sensitivity in skeletal muscle, we per-
formed in vitro studies in L6E9 myotubes. Our data showed
that acute (1 hr) and chronic (24 hr) treatment with rCT-1 signif-Celicantly increased insulin-stimulated glucose uptake (Figure 4H)
as well as AKT phosphorylation (Figures 4I and 4J) in these cells.
Furthermore, using isolated soleus muscle, we demonstrated
that AKT is a major mediator in the stimulatory effect of rCT-1
in glucose uptake by muscle (Figure 4K). We also examined
the ability of rCT-1 to regulate insulin signaling and glucose
uptake in fully differentiated 3T3-L1 adipocytes. In the absence
of insulin, rCT-1 treatment was able to activate AKT phosphory-
lation and to increase baseline glucose uptake. Treatment with
rCT-1 (24 hr) also increased insulin-stimulated glucose uptake.
The inhibition of AKT blocked these effects (Figure S4).l Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier Inc. 247
Figure 5. Chronic rCT-1 Treatment Reduces Fat Mass and Corrects Insulin Resistance in Genetic Model of Obesity
(A–C) Changes in daily food intake (A), body weight (B), and body composition (C) (left panel) in ob/obmice before and after treatment with rCT-1 (0.2 mg/kg/day)
or saline (ad libitum controls and PF) during 10 days (n = 6–7); **p < 0.01 and ***p < 0.001, before versus after. Changes in body composition in these animals (right
panel); **p < 0.01 versus saline and ##p < 0.01 rCT-1 versus PF.
(D–F) Whole-body oxygen consumption rate (VO2), energy expenditure, and physical activity in rCT-1-treated ob/ob mice at the end of the treatment.
###p < 0.001 represents differences between the dark and the light cycle.
(G and H) Serum glucose (G) and insulin levels (H) in saline, rCT-1-treated, and PF ob/ob mice.
(I) Insulin tolerance test (ITT) in saline, rCT-1-treated, and PF ob/ob mice (n = 5–6).
(J) Representative western blots and densitometric analysis of insulin-stimulated P-AKT (Ser473) in skeletal muscle and epididymal WAT from saline,
rCT-1-treated, and PF ob/ob mice.
(K) H&E-stained paraffin-embedded sections of epididymalWAT from saline, rCT-1-treated, and PF ob/obmice. Distribution of adipocyte size (n = 5–6); **p < 0.01
and ***p < 0.001 versus PF.
(L) Relative mRNA levels ofHSL, ATGL,UCP1,UCP2, PRDM16, il-6, TFAM, andNRF1 in epididymal WAT from rCT-1-treated ob/obmice in comparison to saline
and PF-treated mice. Data are expressed as fold change relative to saline-treated control considered as 1 (dotted line) (n = 5–6); *p < 0.05, **p < 0.001 versus
saline-treated group, and #p < 0.05 versus rCT-1-treated group.
(M) Basal and isoproterenol-stimulated lipolysis measured by glycerol release in adipocytes isolated from epididymal WAT of saline, rCT-1-treated, and PF ob/ob
mice (n = 4). Results are means ± SEM; *p < 0.05 versus basal (isoproterenol-untreated) adipocytes and #p < 0.05 rCT-1 versus PF in isoproterenol-treated
adipocytes. (See also Figure S5 and Table S2.)
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CT-1 Regulates Glucose and Lipid MetabolismRecombinant CT-1 Reduces Adiposity and Corrects
Insulin Resistance in Genetic and Acquired Models
of Obesity
We then asked whether rCT-1 therapy could reduce adiposity in
a genetic model of obesity. To this end we administered rCT-1
(0.2 mg/kg/day) i.v. to ob/ob mice for 10 days. We observed
that this treatment reduced food intake and significantly dimin-
ished body weight and fat mass compared with both mice in-
jected with saline and PF animals (Figures 5A–5C). Interestingly,
rCT-1-treated mice experienced less loss of leanmass andmore
pronounced decrease of fat stores than the PF group (Figure 5C).
Also, whole-body O2 consumption was significantly increased in248 Cell Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier IncrCT-1-treated animals as compared with saline and PF groups
(Figure 5D). Consonant with the reduction of food intake, PF
animals exhibited an adaptive reduction of EE, which was not
observed in mice receiving rCT-1 (Figure 5E). Differences in
oxygen consumption could not be ascribed to variations in phys-
ical activity, which was similar in saline and rCT-1 treated groups
(PF group exhibited increased locomotor activity due to ‘‘food
seeking behavior’’) (Figure 5F). Neither BAT mass nor mRNA
levels of UCP1 (a key thermogenic molecule) in BAT showed
differences among groups (Figure S5A).
Importantly, in rCT-1-treated mice, we observed a significant
reduction in glycemia and insulinemia together with a significant.
Figure 6. Chronic rCT-1 Treatment Decreases Body Weight, Fat Mass, Glucose, and Insulin Levels in HFD-Fed WT and ct-1 Null Mice
(A–D) Changes in food intake (A), body weight (B), body composition (C), and serum glucose and insulin levels (D) in rCT-1-treated HFD-fed WT mice.
(E–H) Changes in food intake (E), bodyweight (F), andWATweights (G) estimated by the sumof epididymal, retroperitoneal, and subcutaneous depot weights and
serum glucose and insulin levels in rCT-1-treated HFD-fed ct-1/ mice (H). Animals were fed on HFD for 12 weeks followed by 6 days treatment with rCT-1
(0.2 mg/kg/day) or saline (control or PF) (n = 5–10). Data are means ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001 versus saline-treated mice. #p < 0.05, ##p < 0.01,
###p < 0.001 versus PF group. (See also Table S3.)
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(Figures 5G–5I), indicating improvement of insulin sensitivity in
mice given rCT-1. This was confirmed in an additional study
where animals were sacrificed 5 min after insulin administration
(1 U/g). We found a significant increase of AKT phosphorylation
in muscle in rCT-1-treated mice as compared with the other
groups. However, no significant differences were found in AKT
phosphorylation in WAT between mice receiving rCT-1 and PF
group (Figure 5J). In addition to the glucose-lowering effect,
rCT-1 therapy was associated with reduction of total and LDL
cholesterol while TG levels increased, possibly due to fat mobi-
lization (Table S2).
On histological examination, epididymalWAT from ob/obmice
treated with rCT-1 showed smaller adipocytes (Figure 5K),
a finding that was accompanied by upregulation of HSL, UCP2,
and NRF1 compared with PF group. Moreover, upregulation of
UCP1, TFAM, and PRDM16 in concert with downregulation of
il-6 was observed in rCT-1-treated and PF groups compared
with controls receiving saline (Figure 5L). A similar gene expres-
sion pattern was observed in subcutaneous fat (Figure S5B). To
further assess the influence of rCT-1 on fat mobilization, we
determined glycerol release from isolated ob/ob adipocytes ob-
tained from the three experimental groups. Our data showed that
adipocytes from rCT-1-treatedmice exhibited increased lipolytic
response to isoproterenol as compared with PF group (Fig-
ure 5M). Interestingly, treatment with rCT-1 was accompanied
by a significant reduction of proinflammatorymediators including
IL-6, MCP-1, resistin, and t-PAI in serum (Table S2) and by
absence of changes in rectal temperature (data not shown).
Moreover, rCT-1 treatment was not followed by a rebound of
accelerated weight recovery. Weight gain after cessation of the
therapy was comparable in rCT-1 and PF groups, and both re-
sponded similarly to a new course of treatment (Figure S5C).CelTo determine if rCT-1 could ameliorate weight gain and restore
insulin sensitivity in an acquired model of obesity, we adminis-
tered saline or rCT-1 i.v. (0.2 mg/kg/day) during 6 days to WT
and ct-1 null mice receiving HFD for 12 weeks. Also in these
models, we found that treatment with rCT-1 significantly
decreased food intake and diminished body weight, fat mass,
and hyperinsulinemia as compared with PF group (Figure 6
and Table S3).
DISCUSSION
Our data show that CT-1 is a key cytokine controlling energy
balance.Mice lackingCT-1 develop adult-onset obesity, accom-
panied by hyperglycemia, hyperinsulinemia, and hypertrophy of
pancreatic islets mimicking type 2 diabetes. The similarity of
ct-1-deficient mice to the human metabolic syndrome also
extends to the presence of dyslipidemia with increased total
andLDL cholesterol. Inct-1nullmice, thedevelopment of obesity
and the metabolic syndrome is preceded by decreased EE. This
defect is already present in young nonobese animals and
becomes more severe with aging. Our data clearly show that
CT-1 deficiency predisposes to obesity and dyslipidemia from
the early ages of life, as shown in young ct-1 null mice when sub-
jected to HFD. In keeping with a function of CT-1 as a regulator of
energy metabolism, we observed that ct-1mRNA is upregulated
during fasting and downregulated by refeeding inWAT, liver, and
muscle, indicating that CT-1 behaves as a nutrient sensor.
Other gp130 ligands such as IL-6 and CNTF have been re-
ported to influence energy metabolism (Febbraio, 2007; Watt
et al., 2006). However, the role of CT-1 in fuel homeostasis
appears to be unique. At variance with ct-1, obesity has not
been reported in cntf null mice, although CNTF administration
causes significant reduction of food intake (Masu et al., 1993).l Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier Inc. 249
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While some reports showed that il-6 null mice were hyperphagic
and developed mature-onset obesity (Wallenius et al., 2002),
other investigators did not observe obesity or abnormal lipid
metabolism in those animals (Di Gregorio et al., 2004). In contrast
to other deficiencies of gp130 ligands, ct-1 null mice represent
a model of hypophagic obesity. In these animals excessive
weight gain takes place in the presence of reduced food intake,
possibly as a result of decreased EE. Although the cause of
anorexia in these animals should be further investigated, it may
be a compensatory mechanism to slow down excessive weight
gain as result of low EE. Neither alterations in physical activity nor
thermogenesis seems to account for the low EE observed in ct-1
null mice under baseline conditions, the more obvious candidate
being the reduced metabolic rate. Nevertheless, the underlying
biochemical/molecular mechanisms remain to be elucidated.
A striking feature of mature ct-1/ mice is the presence of a
high RQ, indicative of impaired fat utilization. It has been re-
ported that increased lipid availability observed in obesity
enhances the capacity of muscle for fat oxidation (Hancock
et al., 2008; Turner et al., 2007). However, in obese ct-1 null
mice (12 months old), fatty acid oxidation was similar to age-
matched WT animals, suggesting an impaired capacity to adjust
fat oxidation to increased fat mass. Along these lines, ct-1/
young animals were more prone to develop obesity and dyslipi-
demia than WT mice under the same obesogenic environment,
confirming the difficulty of ct-1-deficient mice to buffer the
excess of dietary fat availability from the early ages of life.
While insulin resistance and type 2 diabetes are found in old
obese ct-1-deficient mice, young nonobese ct-1/ animals
manifest normal insulin sensitivity. This is similar to what is
observed in il-6 knockout mice in which insulin resistance
appears to be secondary to obesity (Wallenius et al., 2002).
Together with excessive weight gain, adult ct-1 null mice also
manifest impaired fat mobilization, as reflected by downregula-
tion of lipolytic genes and decreased lipolytic response to
b-adrenergic agonists in WAT. These alterations can contribute
to accumulation of body fat and may be related to insulin resis-
tance (Jocken et al., 2007; Villena et al., 2004). Moreover, adipo-
cytes from mature obese ct-1 null mice have low mitochondrial
DNA content and diminished oxygen consumption together
with reduced expression of critical genes influencing mitochon-
drial biogenesis such as PGC-1a and eNOS. These alterations
are in keeping with reports showing defective mitochondrial
content in WAT in both genetic and fat-induced obesity (Rong
et al., 2007). The fact that adipocytes from young ct-1/ mice
did not exhibit any of the aforementioned disturbances suggests
that they are a consequence of obesity. However, we cannot
totally rule out that the lack of CT-1 can contribute to aggravate
these changes.
The impact of CT-1 deficiency on energy homeostasis promp-
ted us to analyze the metabolic effects of rCT-1 administration.
Pharmacological doses of rCT-1 caused a marked reduction of
body weight not only in ct-1-deficient mice but also in WT lean
and diet-induced-obese mice. This effect was leptin indepen-
dent, as was also found in ob/ob mice. The antiobesity proper-
ties of rCT-1 were related to the anorexigenic activity of the
cytokine and to its ability to increase EE. Similarly to leptin and
CNTF (Cota et al., 2006, 2008), rCT-1 induces hypophagia by250 Cell Metabolism 14, 242–253, August 3, 2011 ª2011 Elsevier Incstimulating hypothalamic STAT-3 and S6 phosphorylation.
Also, rCT1 shares with leptin and CNTF the property to increase
EE, but the underlying mechanism appears to be different, as
these two cytokines, but not rCT-1, upregulate UCP1 in BAT
(Blu¨her et al., 2004; Rouru et al., 1999). In contrast with the
lack of effect of rCT-1 on BAT, this cytokine exerts a dramatic
remodeling of WAT associated with decreased fat mass. In WT
mice reduction of adipocyte size was accompanied by downre-
gulation of lipogenic genes and upregulation of genes involved in
lipolysis and fatty acid oxidation. Also, rCT-1 upregulates UCP2
and genes controlling mitochondrial biogenesis (TFAM, NRF1,
and eNOS) together with an elevation in the expression of
mtDNA-encoded protein COX1 and an increase in mitochondrial
mass and oxygen consumption by isolated adipocytes. These
changes in WAT are associated with increased FFA oxidation
and upregulation of genes that typify BAT phenotype such as
UCP1, PRDM16, and Dio2 (Seale et al., 2007). Similar changes
are observed in gonadal and subcutaneous WAT from rCT-1-
treated ob/ob mice. Analogous metabolic remodeling of adipo-
cytes has been described for CNTF. However, there are some
important differences between CNTF and CT-1. CNTF does
not upregulate UCP1 in WAT, despite increasing PGC1a
mRNA, suggesting that CNTF induces mitochondrial biogenesis
in adipose tissue but does not enhance the capacity for un-
coupled respiration (Crowe et al., 2008). Importantly, rCT-1 is
able to directly upregulate UCP1 and Dio2 in cultured adipo-
cytes, while CNTF has no comparable effect on these genes,
indicating nonredundancy in the biological activities of these
two cytokines. All these findings reveal that CT-1 can activate
fat utilization in WAT, which might explain the adipose-tissue-
lowering effect of this cytokine (Hoehn et al., 2010).
Interestingly, we found that rCT-1 administration decreases
both fasting and postprandial RQ, causes a rapid clearance of
FFA from plasma after a lipid load, reduces postprandial hyper-
triglyceridemia, upregulates genes involved in FFA oxidation in
muscle, and increases the ability of skeletal muscle to oxidize
palmitate. These data show that CT-1, in addition to promoting
fat utilization in WAT, boosts FFA oxidation in muscle. AMPK is
considered to be amaster switch in the regulation of lipid metab-
olism, and its activation stimulates mitochondrial biogenesis and
fatty acid oxidation in muscle (Hardie, 2008; Viollet et al., 2003).
Our data demonstrate that rCT-1 activates AMPK in muscle and
that AMPKa2 mediates the stimulatory effect of CT-1 on fatty
acid oxidation, as has also been reported for leptin and CNTF
(Minokoshi et al., 2002; Watt et al., 2006). The mechanisms by
which rCT-1 activates AMPK remain to be defined but will be crit-
ical for our understanding of rCT-1 signaling in skeletal muscle.
In humans with the metabolic syndrome, serum CT-1 levels
are increased, and it has been proposed that this cytokine might
cause insulin resistance (Natal et al., 2008). In contrast with this
view, our data indicate that CT-1 displays glucose-lowering
activity. This concept is supported by the following findings: (1)
rCT-1 activates AKT in muscle, (2) pretreatment of mice with
rCT-1 enhances insulin-induced AKT activation in skeletal
muscle, (3) in vitro incubation of L6E9 myocytes with rCT-1 in-
creases insulin-mediated AKT phosphorylation and glucose
uptake, (4) administration of rCT-1 reduces glycemia after
a sugar-rich meal, and (5) rCT-1 corrects hyperglycemia in
STZ-treated insulin-deficient mice, an effect that is remarkable,.
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tion independently of insulin. In consonance with these effects,
chronic administration of rCT-1 is able to reverse insulin resis-
tance in obese mice. It seems possible that the ability of CT-1
to enhance FFA oxidation may contribute to its insulin-sensi-
tizing properties, since high levels of FFA have been suggested
to cause insulin resistance in all major insulin target organs
(Boden, 2008). Importantly, rCT-1 enhances insulin signaling in
muscle, and it should be noted that the muscle is the largest
insulin-sensitive tissue that contributes up to 90% of the
insulin-stimulated glucose disposal in healthy individuals (Kris-
tiansen and Mandrup-Poulsen, 2005). This property is shared
with CNTF (Watt et al., 2006), while the role of IL-6 on insulin
sensitivity remains controversial (Kristiansen and Mandrup-
Poulsen, 2005). With respect to the interaction of CT-1 and
insulin in adipose tissue, our data both in vivo (Figure 4) and
in vitro (Figure S4) argue against the hypothesis that CT-1 may
be a mediator of impaired insulin signaling in adipocytes, as
previously suggested (Zvonic et al., 2004).
CT-1 has already been shown to possess cytoprotective and
hypotensor properties (Calabro` et al., 2009). According to these
data and to themetabolic effects described for CT-1 in this paper,
we may hypothesize that the reported overproduction of CT-1 in
obese subjects with metabolic syndrome (Natal et al., 2008),
hypertension (Pembertonetal., 2005), andcoronaryarterydisease
(Talwar et al., 2001) could be a protective mechanism to counter-
act the emergence of obesity-related disorders such as type 2 dia-
betes or cardiovascular dysfunctions. Indeed, our data point to
CT-1 as a promising therapy for obesity and linked metabolic
disorders. This is not only because CT-1 activates fat utilization
and improves glucose homeostasis but also because it pos-
sesses anorexigenic properties. Nevertheless, it should be con-
sidered that chronic administration of CT-1 has been shown to
promote heart hypertrophy and myocardium remodeling in mice
(Bordet et al., 1999; Pennica et al., 1995). On the other hand, cyto-
kines of the gp130 family might induce inflammatory responses.
However,we foundneither signsof cardiac toxicity, normanifesta-
tions of systemic inflammatory reaction inmice treatedwith rCT-1
for 6–10 days at the doses used in this study. Therefore, there are
grounds for hope that CT-1 might represent a promising thera-
peutic agent of utility in the metabolic syndrome.
EXPERIMENTAL PROCEDURES
Animals
ct-1 null mice were generated as described by Oppenheim et al. (2001). We
analyzed mice backcrossed into a C57BL/6J background for 11 generations
(provided by Diane Pennica, Genentech, and Bettina Holtmann, University of
Wuerzburg, Germany). C57BL/6J mice were originally obtained from The
Jackson Laboratory (Bar Harbor, ME). AMPKa2/ were generated as
described (Viollet et al., 2003) and used at 8 weeks of age. All experimental
procedures were approved by the University of Navarra Ethics Committee.
Body Composition Analysis
Whole animal body composition wasmeasured in live conscious animals using
QMR technology (EchoMRI-100-700, Echo Medical Systems, Houston, TX).
Food Intake, Indirect Calorimetry, and Locomotor Activity
Body weight and food intake were measured three times per week in WT and
ct-1/ mice from 2 to 12 months old. EE was measured by indirect calorim-
etry. Oxygen consumption (VO2) and carbon dioxide production (VCO2) wereCelmeasured using the Oxylet System (Panlab, Spain), which was also used for
continuous recording of locomotor activity through extensiometric weight
transducers placed below the home cage.
Treatments with rCT-1
Chronic effects of rCT-1 (6 or 10 days therapy) were evaluated in different
experimental models fed with NCD or HFD as well as in ob/ob mice. We
also determined the acute effects of rCT-1 on postprandial lipemia and glyce-
mia in normal mice and on glucose metabolism in STZ-induced diabetic mice
(see Supplemental Experimental Procedures).
Biochemistry
All serummeasurements were done on mice fasted for 16 hr, unless otherwise
indicated, using a Cobas Mira Autoanalyzer (Roche Diagnostic, Basel,
Switzerland) (see Supplemental Experimental Procedures).
Sensitivity to Insulin
Insulin sensitivity was evaluated by ITT and insulin signaling (see Supplemental
Experimental Procedures).
Lipolysis
We performed ex vivo lipolysis in adipocytes isolated from epididymal fat.
Isolated adipocytes were incubated in Krebs-Ringer HEPES buffer with or
without 106 M isoproterenol during 90 min at 37C. Lipolysis was evaluated
by the determination of the amount glycerol released into the media.
Adipocyte Oxygen Consumption, Mitochondrial Content,
and Mitochondrial DNA
Adipocytes were isolated from epididymal fat, and oxygen consumption was
measured in a BD Oxygen Biosensor System plate (BD Biosciences) as previ-
ously described (Wilson-Fritch et al., 2004). Mitochondrial mass was deter-
mined in isolated adipocytes using MitoTracker Green FM (Molecular Probes,
Invitrogen). Total DNA was extracted from epididymal fat using QIAamp DNA
kit (QIAGEN), and mtDNA was calculated using real-time quantitative PCR as
previously described (Bonnard et al., 2008).
Histological Analysis
Sections of paraffin-embedded tissues were stained with H&E. Adipocyte cell
size was determined using Matlab 7.1.0.83 R14 (SP13) and diplid 1.6 (http://
www.diplib.org/) software. At least 300 cells fromeach sampleweremeasured.
Palmitate Oxidation in Muscle and Adipose Tissue
Palmitate oxidation was determined in fragments of adipose tissue andmuscle
strips as described (Hoehn et al., 2010) (see Supplemental Experimental
Procedures).
Real-Time Quantitative PCR, Protein Extraction, and Western
Blotting
See Supplemental Experimental Procedures.
2-Deoxy-D-[3H]Glucose Uptake in Cells and Isolated Soleus Muscle
L6E9 rat skeletal muscle cell line and 3T3-L1 adipocytes were grown, and
2-deoxy-d-[3H]glucose uptake was performed as previously reported (Sua´rez
et al., 2001). 2DG uptake was also determined in muscle strips as described
(Dray et al., 2008) (see Supplemental Experimental Procedures).
Statistical Analyses
Results are expressed as the mean ± SEM. Statistical analyses were con-
ducted using the GraphPad Prism software version 4.00 for Windows (Graph-
Pad Software). Data were tested for normality and subjected to t tests or one-
way ANOVA with Tukey’s posttest, unless otherwise indicated. The adipocyte
size distribution was analyzed by the Wilcoxon signed-rank test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, three tables, and Supplemental References and can be found
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